X
[{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals' CDR132 Demonstrates Improvement of Heart Function in Chronic Heart Failure Model","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardior Raises \u20ac64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Phenex Pharmaceuticals","sponsor":"OrsoBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Phenex Pharmaceuticals"}]
Find Drugs for Cardiology/Vascular Diseases in Phase I Clinical Development in GERMANY
Filters
Details:
TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.
Lead Product(s):
TLC-2716
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TLC-2716
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
OrsoBio
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
November 02, 2022
Details:
The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.
Lead Product(s):
CDR132L
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: CDR132L
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Inkef Capital
Deal Size: $76.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
August 25, 2021
Details:
The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Lead Product(s):
CDR132L
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: CDR132L
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 29, 2021
Details:
The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Lead Product(s):
CDR132L
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: CDR132L
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 22, 2020
Details:
In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.
Lead Product(s):
CDR132L
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 31, 2020